Key terms

About IMVT

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IMVT news

Apr 16 3:04pm ET Immunovant management to meet with Piper Sandler by TipRanks Mar 27 4:07pm ET Immunovant initiated with an Outperform at Oppenheimer by TipRanks Mar 21 1:15pm ET Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials by TipRanks Mar 21 10:54am ET Roche’s mixed myasthenia gravis data sending these stocks in opposite directions by TipRanks Mar 21 10:54am ET Roche’s mixed myasthenia gravis data sending these stocks in opposite directions by TipRanks Mar 21 8:18am ET Tourmaline Bio might see weakness today after Roche MG data, says Truist by TipRanks Mar 21 8:12am ET Immunovant rallies after Chugai myasthenia gravis study failure by TipRanks Mar 13 5:25am ET Immunovant Inc.: A Strong Buy on IMVT-1402’s Market Potential and Upcoming Clinical Catalysts by TipRanks Mar 13 5:17am ET Immunovant initiated with a Buy at Goldman Sachs by TipRanks Mar 12 7:51am ET Immunovant awarded U.S. patent for IMVT-1402 by TipRanks Feb 20 5:22am ET Immunovant initiated with an Overweight at JPMorgan by TipRanks Feb 15 1:16am ET Buy Rating Affirmed on Immunovant’s Promising Pipeline and Strategic Clinical Advancements by TipRanks Feb 14 7:17pm ET Wolfe starts Immunovant at Outperform, says excited about catalyst path by TipRanks Feb 14 4:16pm ET Immunovant initiated with an Outperform at Wolfe Research by TipRanks Feb 13 6:20am ET Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT) by TipRanks Feb 13 6:16am ET Buy Rating Affirmed: Immunovant’s Expansion and IMVT-1402’s Market Potential by TipRanks Feb 13 5:55am ET Buy Rating Justified: Immunovant’s Strategic Clinical Advancements and Lead Drug Candidate Promise by TipRanks Feb 13 5:03am ET Buy Rating Affirmed on Immunovant Amidst Strategic Growth and Pipeline Strength by TipRanks Feb 13 4:59am ET Immunovant (IMVT) Poised for Growth: A Buy Rating Backed by Strong Pipeline and Upcoming Catalysts by TipRanks Feb 13 1:00am ET Immunovant, Inc. Is Worried About This – Should You Be Worried Too? by TipRanks Feb 12 3:04pm ET Immunovant options imply 3.5% move in share price post-earnings by TipRanks Feb 12 12:47pm ET Immunovant remains attractive despite stock underperformance, says Wells Fargo by TipRanks Feb 12 7:02am ET Immunovant reports Q3 EPS (36c), consensus (43c) by TipRanks Feb 05 3:55pm ET Immunovant’s Buy Rating: Market Opportunities and Positive Trial Outcomes for Batoclimab by TipRanks

No recent press releases are available for IMVT

IMVT Financials

1-year income & revenue

Key terms

IMVT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IMVT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming